company background image
QGEN

Qiagen NYSE:QGEN Stock Report

Last Price

US$46.63

Market Cap

US$10.6b

7D

6.7%

1Y

-4.0%

Updated

26 Jun, 2022

Data

Company Financials +
QGEN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends0/6

QGEN Stock Overview

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

Qiagen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Qiagen
Historical stock prices
Current Share PriceUS$46.63
52 Week HighUS$58.00
52 Week LowUS$41.32
Beta0.32
1 Month Change2.19%
3 Month Change-2.87%
1 Year Change-3.96%
3 Year Change14.99%
5 Year Change39.07%
Change since IPO2,275.03%

Recent News & Updates

May 26
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

QGENUS Life SciencesUS Market
7D6.7%8.4%6.6%
1Y-4.0%-15.9%-18.4%

Return vs Industry: QGEN exceeded the US Life Sciences industry which returned -15.9% over the past year.

Return vs Market: QGEN exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is QGEN's price volatile compared to industry and market?
QGEN volatility
QGEN Average Weekly Movement3.9%
Life Sciences Industry Average Movement11.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: QGEN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: QGEN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19866,000Thierry Bernardhttps://www.qiagen.com

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

Qiagen Fundamentals Summary

How do Qiagen's earnings and revenue compare to its market cap?
QGEN fundamental statistics
Market CapUS$10.61b
Earnings (TTM)US$538.69m
Revenue (TTM)US$2.31b

19.7x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
QGEN income statement (TTM)
RevenueUS$2.31b
Cost of RevenueUS$752.86m
Gross ProfitUS$1.56b
Other ExpensesUS$1.02b
EarningsUS$538.69m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.37
Gross Margin67.45%
Net Profit Margin23.29%
Debt/Equity Ratio60.0%

How did QGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is QGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QGEN?

Other financial metrics that can be useful for relative valuation.

QGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.9x
Enterprise Value/EBITDA12.5x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does QGEN's PE Ratio compare to its peers?

QGEN PE Ratio vs Peers
The above table shows the PE ratio for QGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average38.3x

Price-To-Earnings vs Peers: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (38.3x).


Price to Earnings Ratio vs Industry

How does QGEN's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?

Price-To-Earnings vs Industry: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the US Life Sciences industry average (30.5x)


Price to Earnings Ratio vs Fair Ratio

What is QGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QGEN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.7x
Fair PE Ratio21.2x

Price-To-Earnings vs Fair Ratio: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).


Share Price vs Fair Value

What is the Fair Price of QGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QGEN ($46.63) is trading below our estimate of fair value ($72.98)

Significantly Below Fair Value: QGEN is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: QGEN is poor value based on its PEG Ratio (2.8x)


Discover undervalued companies

Future Growth

How is Qiagen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


7.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QGEN's forecast earnings growth (7% per year) is above the savings rate (1.9%).

Earnings vs Market: QGEN's earnings (7% per year) are forecast to grow slower than the US market (14% per year).

High Growth Earnings: QGEN's earnings are forecast to grow, but not significantly.

Revenue vs Market: QGEN's revenue (6% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: QGEN's revenue (6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (12.9%).


Discover growth companies

Past Performance

How has Qiagen performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


47.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: QGEN has high quality earnings.

Growing Profit Margin: QGEN's current net profit margins (23.3%) are higher than last year (21.7%).


Past Earnings Growth Analysis

Earnings Trend: QGEN's earnings have grown significantly by 47% per year over the past 5 years.

Accelerating Growth: QGEN's earnings growth over the past year (20.1%) is below its 5-year average (47% per year).

Earnings vs Industry: QGEN earnings growth over the past year (20.1%) underperformed the Life Sciences industry 21%.


Return on Equity

High ROE: QGEN's Return on Equity (16.6%) is considered low.


Discover strong past performing companies

Financial Health

How is Qiagen's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: QGEN's short term assets ($2.1B) exceed its short term liabilities ($957.3M).

Long Term Liabilities: QGEN's short term assets ($2.1B) exceed its long term liabilities ($2.0B).


Debt to Equity History and Analysis

Debt Level: QGEN's net debt to equity ratio (22.1%) is considered satisfactory.

Reducing Debt: QGEN's debt to equity ratio has increased from 44.2% to 60% over the past 5 years.

Debt Coverage: QGEN's debt is well covered by operating cash flow (36.9%).

Interest Coverage: QGEN's interest payments on its debt are well covered by EBIT (15.8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Qiagen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Thierry Bernard (56 yo)

2.67yrs

Tenure

US$2,016,000

Compensation

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board and had been its Interim Chief Executive Officer since October 2019 un...


CEO Compensation Analysis

Compensation vs Market: Thierry's total compensation ($USD2.02M) is below average for companies of similar size in the US market ($USD13.61M).

Compensation vs Earnings: Thierry's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: QGEN's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: QGEN's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QGEN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Qiagen N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Qiagen N.V.
  • Ticker: QGEN
  • Exchange: NYSE
  • Founded: 1986
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$10.606b
  • Shares outstanding: 227.45m
  • Website: https://www.qiagen.com

Number of Employees


Location

  • Qiagen N.V.
  • Hulsterweg 82
  • Venlo
  • Limburg
  • 5912 PL
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.